FY2025 Earnings Estimate for Qiagen Issued By Zacks Research

Qiagen N.V. (NYSE:QGEN) – Investment analysts at Zacks Research cut their FY2025 earnings per share (EPS) estimates for Qiagen in a report issued on Thursday, January 22nd. Zacks Research analyst Team now forecasts that the company will post earnings per share of $2.38 for the year, down from their prior forecast of $2.47. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q2 2026 earnings at $0.66 EPS, FY2026 earnings at $2.57 EPS, Q4 2027 earnings at $0.74 EPS and FY2027 earnings at $2.85 EPS.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.61 by $0.03. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The firm had revenue of $532.58 million during the quarter, compared to analysts’ expectations of $525.68 million. During the same quarter in the prior year, the firm posted $0.60 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis.

Several other analysts have also weighed in on QGEN. Citigroup lowered shares of Qiagen from a “buy” rating to a “neutral” rating and decreased their target price for the company from $57.89 to $52.63 in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Wall Street Zen lowered Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. UBS Group reissued a “neutral” rating on shares of Qiagen in a report on Wednesday, January 21st. Finally, Barclays restated an “overweight” rating and set a $57.89 target price (up previously from $55.79) on shares of Qiagen in a research report on Monday, December 15th. Two equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Qiagen currently has a consensus rating of “Hold” and a consensus target price of $53.04.

Qiagen Trading Down 2.4%

Shares of Qiagen stock opened at $54.29 on Monday. Qiagen has a 52-week low of $39.61 and a 52-week high of $57.81. The firm has a market capitalization of $11.46 billion, a PE ratio of 28.03, a price-to-earnings-growth ratio of 2.67 and a beta of 0.66. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.60 and a quick ratio of 2.30. The company’s fifty day moving average price is $49.04 and its two-hundred day moving average price is $49.53.

Hedge Funds Weigh In On Qiagen

Institutional investors have recently bought and sold shares of the business. Danske Bank A S bought a new stake in shares of Qiagen during the third quarter worth $36,000. Smartleaf Asset Management LLC lifted its position in Qiagen by 1,383.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after buying an additional 830 shares in the last quarter. MAI Capital Management grew its holdings in Qiagen by 998.9% during the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after acquiring an additional 889 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Qiagen by 400.5% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after acquiring an additional 849 shares during the last quarter. Finally, Allworth Financial LP increased its position in Qiagen by 260.1% in the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock valued at $53,000 after acquiring an additional 796 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.